Page 15 - ஜப்பானிய அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Covid : ce qu il faut retenir de la journée du jeudi 20 mai
lesechos.fr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lesechos.fr Daily Mail and Mail on Sunday newspapers.
AstraZeneca Covid-19 vaccine wins emergency use authorisation in Japan | 21 May 2021
stockmarketwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stockmarketwire.com Daily Mail and Mail on Sunday newspapers.
Covid-19: le Japon donne son feu vert réglementaire pour les vaccins Moderna et AstraZeneca
bfmtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bfmtv.com Daily Mail and Mail on Sunday newspapers.
in clinical practice.
The study, with target enrollment of 1500 patients across Europe, will evaluate the effectiveness, safety, and patient-reported outcomes (PROs) in patients with moderate to severe active RA while receiving filgotinib in a real-world setting for up to two years. Mobile device technology will play a central role in collection of PROs, allowing data collection to begin within the first weeks of treatment. This may also prove to be an effective tool during the pandemic, while in-person clinic visits are harder to achieve.
FILOSOPHY will enable the gathering of comprehensive real-world data in a population that may not be fully represented in clinical trials, as randomized, placebo-controlled trials require strict patient inclusion criteria. These data will expand the evidence base to support the appropriate use of filgotinib in clinical practice.
Galapagos NV: Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting
-
Mechelen
that the first patient has been enrolled
i
. The goal with patients with in clinical practice.
The study, with target enrollment of 1500 patients across Europe, will evaluate the effectiveness, safety, and patient-reported outcomes (PROs) in patients with moderate to severe active RA while receiving filgotinib in a real-world setting for up to two years. Mobile device technology will play a central role in collection of PROs, allowing data collection to begin within the first weeks of treatment. This may also prove to be an effective tool during the pandemic, while in-person clinic visits are harder to achieve.